Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, Japan.
Neurosurgery. 2010 Jan;66(1):158-64; discussion 164. doi: 10.1227/01.NEU.0000363153.62579.FF.
Cerebral vasospasm remains a major cause of morbidity and mortality. Milrinone, a bipyridine phosphodiesterase III inhibitor, is a potent member of the inodilator class of cardiac agents for vasospasm and is injected intra-arterially or intracisternally. There have been no studies investigating the duration of action (context-sensitive half-life) of milrinone for vasospasm or the most effective route of administration (intra-arterial versus intracisternal). We examined the effects of intracisternal and intra-arterial injection of milrinone on chronic cerebral vasospasm in dogs.
A double-hemorrhage canine model was used. In a preliminary isometric tension study of canine vasospastic basilar arteries, the vasodilatory effects of milrinone were examined 7 days after an initial injection of blood. Milrinone was injected intracisternally (0.1 mg, 0.47 mmol/L) or intra-arterially (0.3 mg/kg, 1.2 mmol/L), and angiograms were performed 30, 60, 120, 180, 240, 300, and 360 minutes later on day 7.
Milrinone produced concentration-dependent vasodilation and was effective intracisternally, resulting in significant dilation until 180 minutes after injection and a tendency for dilation until 240 minutes. The effect of intra-arterial injection was not as significant compared with an intracisternal injection, resulting in significant dilation only at 180 minutes after intra-arterial injection.
Intracisternal injection of milrinone was more effective than intra-arterial injection for chronic cerebral vasospasm in dogs because intracisternal injection produced a higher concentration in vasospastic arteries (0.034-0.068 mmol/L intracisternally versus 0.016 mmol/L intra-arterially).
脑血管痉挛仍然是发病率和死亡率的主要原因。米力农,双吡啶磷酸二酯酶 III 抑制剂,是一种有效的血管扩张剂和心肌药物类成员,用于血管痉挛,并通过动脉内或脑室内注射。目前还没有研究调查米力农用于血管痉挛的作用持续时间(敏感半衰期)或最有效的给药途径(动脉内与脑室内)。我们研究了脑室内和动脉内注射米力农对犬慢性脑血管痉挛的影响。
采用双出血犬模型。在犬基底动脉痉挛的初步等长张力研究中,在初次注血 7 天后,检查米力农的血管扩张作用。米力农脑室内(0.1mg,0.47mmol/L)或动脉内(0.3mg/kg,1.2mmol/L)注射,在第 7 天的 30、60、120、180、240、300 和 360 分钟后进行血管造影。
米力农产生浓度依赖性血管扩张作用,并在脑室内有效,直至注射后 180 分钟仍有显著扩张作用,并持续至 240 分钟。与脑室内注射相比,动脉内注射的效果不那么显著,仅在动脉内注射后 180 分钟有显著扩张作用。
与动脉内注射相比,脑室内注射米力农对犬慢性脑血管痉挛更有效,因为脑室内注射在痉挛血管中产生更高的浓度(脑室内 0.034-0.068mmol/L 与动脉内 0.016mmol/L)。